Trials / Completed
CompletedNCT00163501
Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Trial to Assess the Long Term Safety of Ciclesonide, Applied as a Nasal Spray (200 Mcg, Once Daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Patients 12 Years and Older
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of perennial allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ciclesonide |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2005-09-14
- Last updated
- 2016-11-30
Locations
41 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00163501. Inclusion in this directory is not an endorsement.